The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s disease
Ethics statement The protocol and recruitment materials were approved by the institutional review boards or ethics committees at…
